Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report

The emergence of epidermal growth factor receptor (EGFR) exon 20 p.C797S is one of the major resistance mechanisms for osimertinib. However, there are no standard of care for non-small cell lung cancer (NSCLC) patients after acquiring EGFR C797S currently, which brings significant challenges to post...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Rengui, Song, Lei, Zhang, Wenwen, Shao, Lin, Li, Xi, Li, Xiangyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093742/
https://www.ncbi.nlm.nih.gov/pubmed/33958875
http://dx.doi.org/10.2147/OTT.S298655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093742/
https://www.ncbi.nlm.nih.gov/pubmed/33958875
http://dx.doi.org/10.2147/OTT.S298655

Ejemplares similares